Fresenius Medical Care AG & Co. (NYSE:FMS) announced its quarterly earnings results on Tuesday. The company reported $1.18 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.57, Briefing.com reports. The business had revenue of $4.43 billion for the quarter, compared to analyst estimates of $5.48 billion. Fresenius Medical Care AG & Co. had a return on equity of 11.51% and a net margin of 7.04%. The company’s quarterly revenue was up .3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.27 EPS.
Shares of Fresenius Medical Care AG & Co. (NYSE FMS) traded down $1.82 during trading hours on Tuesday, hitting $52.92. The stock had a trading volume of 305,376 shares, compared to its average volume of 145,099. Fresenius Medical Care AG & Co. has a fifty-two week low of $41.01 and a fifty-two week high of $57.94. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.22 and a quick ratio of 0.98. The stock has a market cap of $33,446.17, a price-to-earnings ratio of 23.73, a price-to-earnings-growth ratio of 2.07 and a beta of 0.52.
Several equities research analysts have recently commented on the company. Royal Bank of Canada reissued a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research note on Tuesday. SunTrust Banks set a $62.00 price target on Fresenius Medical Care AG & Co. and gave the stock a “buy” rating in a research note on Thursday, December 21st. Nord/LB reissued a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Wednesday, December 27th. UBS Group raised Fresenius Medical Care AG & Co. from a “sell” rating to a “neutral” rating in a research note on Thursday, January 4th. Finally, DZ Bank reissued a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Monday, November 13th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $56.00.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3226446/fresenius-medical-care-ag-co-fms-releases-quarterly-earnings-results-beats-expectations-by-0-57-eps.html.
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.